Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11745343rdf:typepubmed:Citationlld:pubmed
pubmed-article:11745343lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:11745343lifeskim:mentionsumls-concept:C0020792lld:lifeskim
pubmed-article:11745343lifeskim:mentionsumls-concept:C0242957lld:lifeskim
pubmed-article:11745343lifeskim:mentionsumls-concept:C0007134lld:lifeskim
pubmed-article:11745343lifeskim:mentionsumls-concept:C1368683lld:lifeskim
pubmed-article:11745343lifeskim:mentionsumls-concept:C0003316lld:lifeskim
pubmed-article:11745343lifeskim:mentionsumls-concept:C0872192lld:lifeskim
pubmed-article:11745343lifeskim:mentionsumls-concept:C0449450lld:lifeskim
pubmed-article:11745343pubmed:issue11lld:pubmed
pubmed-article:11745343pubmed:dateCreated2001-12-17lld:pubmed
pubmed-article:11745343pubmed:abstractTextHER-2/neu is a tumor-associated antigen overexpressed in a large variety of human tumors. Eight HER-2/neu peptides displaying HLA-A*0201 anchoring motifs were selected and tested for their binding affinity to HLA-A*0201 and their capacity to elicit cytotoxic T lymphocyte (CTL) responses in both HLA-A*0201 transgenic mice and in HLA-A*0201(+) healthy donors. Two high-affinity (p5 and p48) and one intermediate-affinity (p1023) peptides triggered CTL responses in both transgenic mice and humans, comparable to those observed for the well-known HER2/neu dominant peptide p369. CTL induced in transgenic mice lysed HLA-A*0201(+) RMA cells infected with recombinant HER-2/neu but not cells infected with wild-type vaccinia virus. Human CTL lysed HLA-A*0201(+) HER-2/neu(+) tumor cells of different origins (breast, colon, lung and renal cancer) irrespective of the expression levels of HER-2/neu. Importantly, primed CTL specific for these epitopes were detected in freshly isolated tumor-infiltrating lymphocytes from three renal cell carcinoma patients. Therefore, the HER-2/neu peptides p5, p48 and p1023 may be good candidates for immunotherapy of a broad spectrum of tumors, including renal cell carcinoma.lld:pubmed
pubmed-article:11745343pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11745343pubmed:languageenglld:pubmed
pubmed-article:11745343pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11745343pubmed:citationSubsetIMlld:pubmed
pubmed-article:11745343pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11745343pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11745343pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11745343pubmed:statusMEDLINElld:pubmed
pubmed-article:11745343pubmed:monthNovlld:pubmed
pubmed-article:11745343pubmed:issn0014-2980lld:pubmed
pubmed-article:11745343pubmed:authorpubmed-author:LemonnierFFlld:pubmed
pubmed-article:11745343pubmed:authorpubmed-author:NadlerL MLMlld:pubmed
pubmed-article:11745343pubmed:authorpubmed-author:AlvesPPlld:pubmed
pubmed-article:11745343pubmed:authorpubmed-author:GrossD ADAlld:pubmed
pubmed-article:11745343pubmed:authorpubmed-author:ChouaibSSlld:pubmed
pubmed-article:11745343pubmed:authorpubmed-author:Kosmatopoulos...lld:pubmed
pubmed-article:11745343pubmed:authorpubmed-author:AngevinEElld:pubmed
pubmed-article:11745343pubmed:authorpubmed-author:FiratHHlld:pubmed
pubmed-article:11745343pubmed:authorpubmed-author:CardosoA AAAlld:pubmed
pubmed-article:11745343pubmed:authorpubmed-author:ScardinoAAlld:pubmed
pubmed-article:11745343pubmed:authorpubmed-author:TourdotSSlld:pubmed
pubmed-article:11745343pubmed:authorpubmed-author:Graff-DuboisS...lld:pubmed
pubmed-article:11745343pubmed:issnTypePrintlld:pubmed
pubmed-article:11745343pubmed:volume31lld:pubmed
pubmed-article:11745343pubmed:ownerNLMlld:pubmed
pubmed-article:11745343pubmed:authorsCompleteYlld:pubmed
pubmed-article:11745343pubmed:pagination3261-70lld:pubmed
pubmed-article:11745343pubmed:dateRevised2009-11-19lld:pubmed
pubmed-article:11745343pubmed:meshHeadingpubmed-meshheading:11745343...lld:pubmed
pubmed-article:11745343pubmed:meshHeadingpubmed-meshheading:11745343...lld:pubmed
pubmed-article:11745343pubmed:meshHeadingpubmed-meshheading:11745343...lld:pubmed
pubmed-article:11745343pubmed:meshHeadingpubmed-meshheading:11745343...lld:pubmed
pubmed-article:11745343pubmed:meshHeadingpubmed-meshheading:11745343...lld:pubmed
pubmed-article:11745343pubmed:meshHeadingpubmed-meshheading:11745343...lld:pubmed
pubmed-article:11745343pubmed:meshHeadingpubmed-meshheading:11745343...lld:pubmed
pubmed-article:11745343pubmed:meshHeadingpubmed-meshheading:11745343...lld:pubmed
pubmed-article:11745343pubmed:meshHeadingpubmed-meshheading:11745343...lld:pubmed
pubmed-article:11745343pubmed:meshHeadingpubmed-meshheading:11745343...lld:pubmed
pubmed-article:11745343pubmed:year2001lld:pubmed
pubmed-article:11745343pubmed:articleTitleIdentification of HER-2/neu immunogenic epitopes presented by renal cell carcinoma and other human epithelial tumors.lld:pubmed
pubmed-article:11745343pubmed:affiliationINSERM 487, Institut Gustave Roussy, Villejuif, France.lld:pubmed
pubmed-article:11745343pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:11745343pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:11745343pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11745343lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11745343lld:pubmed